Allergic RhinitisNCT07784491
Sphenopalatine Ganglion Acupuncture for Allergic Rhinitis
A study testing Sphenopalatine Ganglion Acupuncture and Mometasone furoate nasal spray in people with Allergic Rhinitis, run by Zhongshan Torch Development Zone People's Hospital at 1 site in China.
Trial summary
Allergic rhinitis can cause sneezing, a runny or blocked nose, and nasal itching, which may affect daily activities and quality of life. Nasal corticosteroid sprays are commonly used to control these symptoms, but some people may still have bothersome symptoms. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Allergic Rhinitis
- What is being tested?
- Sphenopalatine Ganglion Acupuncture and Mometasone furoate nasal spray
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 150 participants
- Where
- 1 siteChina
- Study dates
- 31 Aug 2026to 20 Jan 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Diagnosis of allergic rhinitis according to the Chinese Guidelines for Diagnosis and Treatment of Allergic Rhinitis (2022 Revision), meeting all of the following criteria:
- At least two of the following symptoms: paroxysmal sneezing, watery rhinorrhea, nasal itching, and nasal obstruction, with symptoms lasting or accumulating for at least 1 hour per day; ocular symptoms such as itching, tearing, or redness may also be present.
- Anterior rhinoscopy or nasal endoscopy showing findings consistent with allergic rhinitis, such as pale or edematous nasal mucosa, turbinate swelling, and watery nasal secretions.
- At least one positive allergen test, including a skin prick test, serum allergen-specific immunoglobulin E (sIgE) test, or nasal allergen provocation test.
- No use of antihistamines, intranasal or systemic corticosteroids, leukotriene receptor antagonists, allergen immunotherapy, or other treatments that may affect efficacy assessment within 2 weeks before enrollment.
- Baseline Total Nasal Symptom Score (TNSS) sufficient for efficacy assessment according to the study protocol.
- Voluntary participation in the study and provision of written informed consent.
Who cannot join
- Presence of acute upper respiratory tract infection, acute or chronic rhinosinusitis, nasal polyps, severe nasal septal deviation, rhinitis medicamentosa, vasomotor rhinitis, infectious rhinitis, or other forms of non-allergic rhinitis.
- Presence of an autoimmune disease or a psychiatric or psychological disorder that may interfere with study participation or outcome assessment.
- Pregnancy or breastfeeding.
- Coagulation disorders, current use of anticoagulant medications, local skin infection at the acupuncture site, a tendency to develop excessive scarring, or inability to tolerate acupuncture.
- Known severe hypersensitivity or contraindication to any component of the study medication or to the study intervention.
- Current participation in another clinical study, or any other condition that, in the investigator's judgment, makes the participant unsuitable for this study.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
Zhongshan Torch Development Zone People's Hospital
Zhongshan, Guangdong
Li, Dr., 076028152158, gye_Li@163.com
About this study
Official title: Sphenopalatine Ganglion Acupuncture for Allergic Rhinitis: A Prospective Randomized Controlled Trial
Allergic rhinitis can cause sneezing, a runny or blocked nose, and nasal itching, which may affect daily activities and quality of life. Nasal corticosteroid sprays are commonly used to control these symptoms, but some people may still have bothersome symptoms.
The purpose of this study is to find out whether adding sphenopalatine ganglion acupuncture to mometasone furoate nasal spray can improve allergic rhinitis symptoms more than using the nasal spray alone, and to evaluate the safety of this treatment.
Adults with moderate-to-severe perennial allergic rhinitis will be randomly assigned to one of two treatment groups. Both groups will use mometasone furoate nasal spray for 4 weeks. Participants in one group will also receive sphenopalatine ganglion acupuncture twice a week for 4 weeks. Researchers will compare changes in nasal symptoms, quality of life, use of rescue medication, clinical examination findings, and adverse events between the two groups. Participants will also be followed after treatment to assess whether the treatment effects are maintained.
- Conditions
- Allergic Rhinitis
- Being tested
- Sphenopalatine Ganglion Acupuncture, Mometasone furoate nasal spray
- Keywords
- Sphenopalatine Ganglion, Allergic Rhinitis, Intranasal Corticosteroid
- Medical subject headings
- Rhinitis, Allergic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Sphenopalatine Ganglion AcupunctureProcedure or surgery
Also called Pterygopalatine Ganglion Acupuncture
Sphenopalatine ganglion acupuncture will be performed twice weekly for 4 consecutive weeks, for a total of 8 treatment sessions. Acupuncture will be performed alternately on the left and right sides without needle retention.
Mometasone furoate nasal sprayDrug
Also called Intranasal Corticosteroid
Mometasone furoate nasal spray will be administered as two sprays into each nostril once daily for 4 consecutive weeks.
| Study group | Role | What they receive |
|---|---|---|
| Intranasal Corticosteroid Group | Active comparator | Participants assigned to this group will receive intranasal corticosteroid treatment alone for 4 weeks. Receives: Drug: Mometasone furoate nasal spray |
| Sphenopalatine Ganglion Acupuncture Group | Experimental | Participants assigned to this group will receive sphenopalatine ganglion acupuncture alone for 4 weeks. Receives: Procedure: Sphenopalatine Ganglion Acupuncture |
| Combination Group | Experimental | Participants assigned to this group will receive sphenopalatine ganglion acupuncture combined with intranasal corticosteroid treatment for 4 weeks. Receives: Procedure: Sphenopalatine Ganglion Acupuncture; Drug: Mometasone furoate nasal spray |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change From Baseline in Total Nasal Symptom Score
Measured: Baseline, Week 2, Week 4, Week 8 and Month 6.
Secondary outcomes (3)
Change From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire Score
Measured: Baseline, Week 2, Week 4, Week 8 and Month 6
Total Non-Nasal Symptom Score
Measured: Baseline, Week 2, Week 4, Week 8 and Month 6.
Change From Baseline in Nasal Examination Score
Measured: Baseline and Week 4.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Aug 2026
- Study start31 Aug 2026 (estimated)
- Primary completion31 Dec 2026 (estimated)
- Study completion20 Jan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Allergic RhinitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Investigator, Outcomes assessor
- Enrolment
- 150 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Zhongshan Torch Development Zone People's Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Junling Li, Zhongshan Torch Development Zone People's Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07784491
- Sponsor's protocol ID
- KY-2026-030
- Status last verified
- Aug 2026
- First submitted
- 21 Aug 2026
- Last updated
- 28 Aug 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Deidentified individual participant data underlying the results reported in the published article.
Study at a glance
From the registry record, last updated by the sponsor on 28 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Sphenopalatine Ganglion Acupuncture for Allergic Rhinitis: A Prospective Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07784491
- Acronym / sponsor ID
- KY-2026-030
- Conditions
- Allergic Rhinitis
- Keywords
- Sphenopalatine Ganglion, Allergic Rhinitis, Intranasal Corticosteroid
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 150 participants (estimated)
- Lead sponsor
- Zhongshan Torch Development Zone People's HospitalUniversity, hospital or other
- Study start
- 31 Aug 2026 (estimated)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 20 Jan 2027 (estimated)
- First posted
- 25 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Allergic rhinitis can cause sneezing, a runny or blocked nose, and nasal itching, which may affect daily activities and quality of life. Nasal corticosteroid sprays are commonly used to control these symptoms, but some people may still have bothersome symptoms.
The purpose of this study is to find out whether adding sphenopalatine ganglion acupuncture to mometasone furoate nasal spray can improve allergic rhinitis symptoms more than using the nasal spray alone, and to evaluate the safety of this treatment.
Adults with moderate-to-severe perennial allergic rhinitis will be randomly assigned to one of two treatment groups. Both groups will use mometasone furoate nasal spray for 4 weeks. Participants in one group will also receive sphenopalatine ganglion acupuncture twice a week for 4 weeks. Researchers will compare changes in nasal symptoms, quality of life, use of rescue medication, clinical examination findings, and adverse events between the two groups. Participants will also be followed after treatment to assess whether the treatment effects are maintained.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Intranasal Corticosteroid Group | Active comparator | Drug: Mometasone furoate nasal sprayParticipants assigned to this group will receive intranasal corticosteroid treatment alone for 4 weeks. |
| Sphenopalatine Ganglion Acupuncture Group | Experimental | Procedure: Sphenopalatine Ganglion AcupunctureParticipants assigned to this group will receive sphenopalatine ganglion acupuncture alone for 4 weeks. |
| Combination Group | Experimental | Procedure: Sphenopalatine Ganglion Acupuncture, Drug: Mometasone furoate nasal sprayParticipants assigned to this group will receive sphenopalatine ganglion acupuncture combined with intranasal corticosteroid treatment for 4 weeks. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (7 listed)
Key exclusion criteria (6 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Sphenopalatine Ganglion AcupunctureAlso: Pterygopalatine Ganglion AcupunctureSphenopalatine ganglion acupuncture will be performed twice weekly for 4 consecutive weeks, for a total of 8 treatment sessions. Acupuncture will be performed alternately on the left and right sides without needle retention. | Procedure or surgery | Combination Group, Sphenopalatine Ganglion Acupuncture Group |
| Mometasone furoate nasal sprayAlso: Intranasal CorticosteroidMometasone furoate nasal spray will be administered as two sprays into each nostril once daily for 4 consecutive weeks. | Drug | Combination Group, Intranasal Corticosteroid Group |
Primary outcome
Change From Baseline in Total Nasal Symptom Score
Time frame: Baseline, Week 2, Week 4, Week 8 and Month 6.
3 secondary outcomes
Change From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire Score
Time frame: Baseline, Week 2, Week 4, Week 8 and Month 6
Total Non-Nasal Symptom Score
Time frame: Baseline, Week 2, Week 4, Week 8 and Month 6.
Change From Baseline in Nasal Examination Score
Time frame: Baseline and Week 4.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Aug 2026.
- Individual participant dataSharing planned: Yes. Deidentified individual participant data underlying the results reported in the published article.
Related trials for Allergic Rhinitis
Not yet recruitingPhase 1
Safety and Tolerability of Fluticasone Propionate 10% Nasal Insert in Participants With Chronic Allergic Rhinitis
Chronic Allergic Rhinitis
RecruitingPhase 3
Specific Immunotherapy With Mannan-Conjugated Allergoids for HDM-Allergic Rhinitis/Rhinoconjunctivitis_MM09-SIT-063.
Allergic Rhinitis, Allergic Rhinoconjunctivitis
RecruitingPhase 3
Specific Immunotherapy With Mannan-Conjugated Allergoids for HDM-Allergic Rhinitis/Rhinoconjunctivitis. MM09-SIT-063.
Allergic Rhinitis, Allergic Rhinoconjunctivitis
Enrolling by invitationObservational study
Allergy, Asthma, and Atopic Eczema in Finland
Asthma, Asthma in Children
Not yet recruitingObservational study
Prevelance of Bronchial Asthma and Allergic Rhinitis Among Children With Nephrotic Syndrom at Sohag University Hospital
Allergic Diseases in Nephrotic Children, Nephrotic Syndrom
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Sphenopalatine Ganglion Acupuncture and Mometasone furoate nasal spray in people with Allergic Rhinitis, run by Zhongshan Torch Development Zone People's Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 28 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Junling Li (+8613189264696, junlingli26@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change From Baseline in Total Nasal Symptom Score (time frame: Baseline, Week 2, Week 4, Week 8 and Month 6.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Aug 2026.